2017-02-06T08:41:48-05:00 2016-06-30 135565207 KPMG LLP 345 PARK AVENUE NEW YORK NY 101540102 990 2015-07-01 135644916 THE LEUKEMIA & LYMPHOMA SOCIETYINC LEUK 9149495213 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 ROSEMARIE A LOFFREDO EVP - CAO & CFO 9148218877 2017-01-30 true DAVID M HIGHFILL P01517891 2127589700 2017-01-30 2015 2021-01-29 14:40:06Z X LOUIS J DEGENNARO 3 INTERNATIONAL DRIVE SUITE 200 RYE BROOK NY 10573 509381899 false X WWW.LLS.ORG X 1949 NY OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES. 28 28 1455 3000000 0 283909984 285638088 0 4913321 -6187940 -7194375 -7722874 281628930 271727274 107996054 88538361 0 85679493 87185045 4709809 4059876 35316836 79057701 74986029 277443057 254769311 4185873 16957963 214485806 217192867 116963860 99112566 97521946 118080301 X OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES. false false 52234348 47209977 A) RESEARCH PROGRAMS: WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVED OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. TO DATE, LLS HAS INVESTED OVER 1 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2016, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 5 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 47 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, AND, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGIANST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECIEVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2016, FOR THE FIFTH YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOLENT LYMPHOMA PATIENTS - DEFINE GENETIC/MOLECULAR PREDISPOSITIONS TO LONG-TERM AND LATE-T 85232201 41328384 B) PATIENT & COMMUNITY SERVICES: AN ESTIMATED 1.24 MILLION PEOPLE ACROSS THE UNITED STATES (US) CURRENTLY BATTLE LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS AN ARRAY OF FREE, COMPREHENSIVE RESOURCES TO BLOOD CANCER PATIENTS, CAREGIVERS, FAMILIES AND FRIENDS OF PATIENTS, ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION; PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PRINT PUBLICATIONS AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES DISEASE AND SUPPORT BOOKLETS AND FACT SHEETS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. EACH YEAR, LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. - 615,479 FREE PRINTED DISEASE AND SUPPORT BOOKLETS, 5,498 DISEASE-FOCUSED FACT SHEETS, AND 141 DVDS WERE ORDERED IN 2016. FINANCIAL ASSISTANCE IN 2016, A COMBINED 40,835,972 WAS DISBURSED TO PATIENTS THROUGH THE CO-PAY ASSISTANCE PROGRAMS (40,029,645) AND THE LLS NATIONAL PATIENT TRAVEL ASSISTANCE PROGRAM, (793,500), AND LLS FINANCIAL ASSISTANCE PROGRAM (12,827). CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2016, 40,029,645 WAS PROVIDED TO PATIENTS THROUGH THE LLS CO-PAY ASSISTANCE PROGRAM. - 18,155 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2016. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM THE SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS WITH TRAVEL AND LODGING EXPENSES RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. TRAVEL ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY. IN 2016, 793,500 WAS PROVIDED TO PATIENTS THROUGH THE LLS SUSAN LANG TRAVEL PROGRAM 1,587 PATIENTS RECEIVED LLS TRAVEL ASSISTANCE IN 2016 FINANCIAL ASSISTANCE PROGRAM FOR CML PATIENTS (PCR PROGRAM) THE FINANCIAL ASSISTANCE PROGRAM FOR CML PATIENTS SUPPORTS QUALIFYING PATIENTS WITH OUT OF POCKET EXPENSES RELATED TO THEIR ROUTINE POLYMERASE CHAIN REACTION (PCR) EXAM. IN 2016, 12,827 WAS PROVIDED TO PATIENTS THROUGH THE PCR PROGRAM 260 PATIENTS RECEIVED LLS PCR ASSISTANCE IN 2016 COMMUNITY PROGRAMS SERVICES ARE PROVIDED IN COMMUNITIES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS BY STAFF (PATIENT ACCESS MANAGERS) AND TRAINED VOLUNTEERS WHO HAVE SPECIFIC SUPPORT AND OUTREACH ROLES. STAFF ARE HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING, PUBLIC HEALTH OR SOCIAL WORK; VOLUNTEERS ARE TYPICALLY PATIENTS OR CAREGIVERS WHO UNDERGO RIGOROUS BACKGROUND CHECKS AND TRAINING. STAFF AND VOLUNTEERS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS, AND PROVIDE COMMUNITY-BASED OUTREACH, EDUCATION, AND SUPPORT IN A VARIETY OF FORMS. LOCAL PATIENT EDUCATION PROGRAMS: IN FY 2016 WE CONDUCTED 43 LOCAL PATIENT EDUCATION PROGRAMS TO 1,893 ATTENDEES. THIRTY-SIX WERE PROGRAMS THAT COVERED DISEASE SPECIFIC TOPICS, SURVIVORSHIP ISSUES, AND/OR EDUCATION ABOUT CANCER CLINICAL TRIALS AND MAKING TREATMENT DECISIONS. OF THESE 36, 12 WERE LOCATED IN AND WERE SPECIFICALLY TAILORED TO UNDERSERVED COMMUNITIES, ESPECIALLY RACIAL AND ETHNIC MINORITY GROUPS AND OLDER ADULTS. SEVEN PROGRAMS WERE FOCUSED ON THE DIAGNOSIS AND TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS OR MPN. REGIONAL BLOOD CANCER CONFERENCES: LLS WORKS TO ELEVATE OUR VISIBILITY IN COMMUNITIES WE SERVE BY HOSTING LARGER-SCALE CONFERENCES, GEARED FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. THESE EVENTS ARE A CATALYST FOR BRINGING MANY DEDICATED PEOPLE TOGETHER TO FOCUS ON BLOOD CANCER AWARENESS, INFORMATION AND THE LATEST ADVANCES IN MEDICAL SCIENCE. THEY ARE DESIGNED FOR PATIENTS AND CAREGIVERS BUT ARE ATTENDED BY SOME LOCAL HEALTHCARE PROFESSIONALS (NURSES AND SOCIAL WORKERS) AS WELL. IN 2016, 16 BCC CONFERENCES WERE HELD WITH 4,805 ATTENDEES LLS COMMUNITY THE ONLINE "LLS COMMUNITY" WAS LAUNCHED ON FEBRUARY 1, 2016. IT WAS DESIGNED TO PROVIDE A WAY FOR PATIENTS AND CAREGIVERS TO: 1) BECOME PART OF A SOCIAL NETWORK TO CONNECT WITH PATIENTS AND CAREGIVERS IN SIMILAR SITUATIONS AND BECOME EMPOWERED; 2) PROVIDE INFORMATION ABOUT ONESELF AND ONE'S DISEASE, TO BECOME PART OF THE RESEARCH TO CURE BLOOD CANCERS; AND 3) GAIN THE LATEST INFORMATION ABOUT ONE'S DISEASE, LEARN ABOUT SURVIVORSHIP ISSUES, AND ABOUT CLINICAL TRIALS. BY THE END OF FY 2016, THERE WERE APPROXIMATELY 2,500 COMMUNITY MEMBERS AND 15,000 RESPONSES TO THE "QUESTIONS OF THE DAY," AS WELL AS CLOSE TO 4,000 COMMENTS POSTED BY USERS FAMILY SUPPORT GROUPS: THROUGHOUT THE US, IN 2016, LLS SUPPORTED OR HOSTED 204 REGISTERED FAMILY SUPPORT GROUP MEETINGS FOR PATIENTS AND THEIR FAMILIES. GROUPS ARE GUIDED BY ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. LLS SUPPORT GROUPS ARE THE PERFECT PLACE TO TALK WITH OTHER PEOPLE AFFECTED BY BLOOD CANCERS, INCLUDING PATIENTS, FAMILY MEMBERS AND CAREGIVERS. THE GROUPS PROVIDE MUTUAL SUPPORT AND OFFER THE OPPORTUNITY TO DISCUSS ANXIETIES AND CONCERNS WITH OTHERS WHO SHARE THE SAME EXPERIENCES. THIS SHARING STRENGTHENS THE FAMILY BOND AND ENHANCES EVERYONE'S ABILITY TO COPE WITH CANCER. PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM: FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT- VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS; REFERRAL IS ALSO PROVIDED BY LLS'S INFORMATION RESOURCE CENTER. -717 FIRST CONNECTIONS WERE MADE ACROSS THE US IN FY 2016. 40255829 C) PUBLIC HEALTH EDUCATION: INFORMATION AND EDUCATION. PAYING FOR MEDICAL CARE, MAKING TREATMENT CHOICES, COMMUNICATING WITH HEALTHCARE PROVIDERS, FAMILY MEMBERS AND FRIENDS-THESE ARE SOME OF THE STRESSES THAT COME WITH A CANCER DIAGNOSIS. LLS'S INFORMATION SPECIALISTS ARE MASTER'S LEVEL ONCOLOGY SOCIAL WORKERS, NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. INFORMATION SPECIALISTS ALSO CONDUCT CLINICAL-TRIAL SEARCHES TO HELP PATIENTS WORK WITH THEIR DOCTORS TO FIND OUT ABOUT SPECIFIC CLINICAL TRIALS. THE INFORMATION RESOURCE CENTER ALSO HAS AN EXPANDING IN-DEPTH CLINICAL TRIAL NAVIGATION SERVICE. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. IN FY 2016: - 26,668 INQUIRIES WERE MADE TO OUR INFORMATION SPECIALISTS. - 12,399 UNIQUE INDIVIDUALS RECEIVED INFORMATION AND/OR SUPPORT FROM INFORMATION SPECIALISTS VIA EMAILS, PHONE, AND ANSWER CHATS. -167 PATIENTS WORKED WITH A CLINICAL TRIAL NAVIGATOR TO RECEIVE COMPREHENSIVE ASSISTANCE WITH CLINICAL TRIAL ENROLLMENT; 49% OF THESE PATIENTS ENROLLED ON A CLINICAL TRIAL. THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, DISCUSSION BOARDS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL- TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. INFORMATIONAL MATERIALS ARE AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. MANY DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS ADDITIONALLY, LLS ALSO SPONSORS TELEPHONE- WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. ALSO AVAILABLE THROUGH THE LLS WEBSITE ARE VIRTUAL LECTURES AND VIDEOS FEATURING DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. IN FY 2016: -20,906 INDIVIDUALS PARTICIPATED IN LLS'S ONLINE DISCUSSION BOARDS -LLS PROVIDED 9 LIVE NATIONAL TELEPHONE-WEB EDUCATION PROGRAMS, WITH 3,032 PARTICIPANTS -THERE WERE 24,078 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, 16,612 VIEWS OF VIDEOS. 15384710 D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. 15384710 193107088 true true false true false false false true false true true true false false false true false true false true true true false true true true false true true true false false false false false false false false true false false false true true true true false false true 614 8 true 1455 true false true CA false false false true true false false false false X 28 28 false false false false true true true true true false true true true true true true true true true true false AK AL AR AZ CA CO CT DE DC FL GA HI ID IL IN KS KY LA MA MD ME MI MN MO MS NH NJ NM NE NY OH OK OR PA PR RI SC TN UT VA WA WI WV X X ROSEMARIE A LOFFREDO 9149495213 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 LOUIS J DEGENNARO PRESIDENT & 40.00 1.00 X 511049 0 55178 ROSEMARIE A LOFFREDO EVP - CAO & 40.00 1.00 X 325143 0 26556 GORDON MILLER JR SVP FINANCE 40.00 5.00 X 257007 0 44252 MARK ROITHMAYR EVP CHIEF RE 40.00 X 360544 0 47654 ANDREW S COCCARI EVP CHIEF PR 40.00 X 151419 0 26842 CLAUDE E EDKINS SVP CHIEF IN 40.00 1.00 X 308347 0 38125 LEE M GREENBERGER SVP CHIEF SC 40.00 X 288435 0 42797 NANCY HALLBERG SVP CHIEF MA 40.00 X 226725 0 26797 JAMES A MASSARA VP APP & TRA 40.00 X 224952 0 35176 OSMAN MAZHAR VP PLATFORM 40.00 X 223521 0 34694 JEFFREY COMO-TERM DEC2014 CHIEF INFORM 40.00 X 130452 0 0 GEORGE J OMIROS-TERM APR15 EVP-CHIEF CA 40.00 X 485575 0 9898 GABRIELLE URQUHART-TERM JUN15 REGIONAL VP 40.00 X 186726 0 10666 JOHN E WALTER - TERM FEB14 PRESIDENT & 0.00 X 146327 0 0 JAMES H DAVIS PHD CHAIR 6.00 2.00 X X 0 0 0 ELIZABETH J CLARK PHD VICE CHAIR 4.00 2.00 X X 0 0 0 PETER B BROCK SECRETARY/TR 4.00 2.00 X X 0 0 0 DONALD PROCTOR AT-LARGE 4.00 2.00 X X 0 0 0 JAMES A BECK BOD MEMBER 4.00 1.00 X 0 0 0 WILLIAM G BEHNKE BOD MEMBER 4.00 X 0 0 0 JORGE L BENITEZ BOD MEMBER 4.00 X 0 0 0 JAMES E BRADNER BOD MEMBER 4.00 X 0 0 0 A DANA CALLOW JR BOD MEMBER 4.00 X 0 0 0 SCOTT A CARROLL BOD MEMBER 4.00 1.00 X 0 0 0 WILLIAM S DALTON PHD BOD MEMBER 4.00 X 0 0 0 GRACIELA E ELETA BOD MEMBER 4.00 X 0 0 0 BERNARD H GARIL BOD MEMBER 4.00 X 0 0 0 FRANCIE HELLER BOD MEMBER 4.00 X 0 0 0 RAANAN HOROWITZ BOD MEMBER 4.00 X 0 0 0 RICHARD M JEANNERET BOD MEMBER 4.00 1.00 X 0 0 0 JOSEPH B KELLEY BOD MEMBER 4.00 X 0 0 0 RALPH E LAWSON BOD MEMBER 4.00 X 0 0 0 MICHELLE LE BEAU PHD BOD MEMBER 4.00 X 0 0 0 GILLES LEGAULT BOD MEMBER 4.00 X 0 0 0 CONNIE LINDSEY BOD MEMBER 4.00 X 0 0 0 STEVEN T ROSEN BOD MEMBER 4.00 X 0 0 0 KENNETH M SCHWARTZ BOD MEMBER 4.00 X 0 0 0 BART SICHEL BOD MEMBER 4.00 X 0 0 0 FRANK O SMITH BOD MEMBER 4.00 X 0 0 0 KATHRYN C VECELLIO BOD MEMBER 4.00 X 0 0 0 LOUISE G WARNER BOD MEMBER 4.00 X 0 0 0 KEITH S WHITE BOD MEMBER 4.00 X 0 0 0 3826222 398635 147 true true false OLIVER STAFFING INC 350 LEXINGTON AV SUITE 401 NEW YORK NY 10016 TEMP STAFFING 5017393 RESOURCE ONE 2900 EAST APACHE STREET TULSA OK 74110 DIRECT MARKETIN 4153198 APPIRIO INC PO BOX 123011 DALLAS TX 75312 IT SOFTWARE DEV 3696159 PATIENT ADVOCACY FOUNDATION 421 BUTLER FARM RD HAMPTON VA 23666 PAT ASSIST PROC 3378284 RESOLUTE MEDIA LLC 137 W 25TH ST NEW YORK NY 10001 DIGITAL MARKETI 2824015 116 1784943 165077259 118775886 1349813 285638088 1480895 1480895 84951 84951 204044790 211713625 -7668835 -7668835 -7668835 17468116 165077259 25748962 -8280846 -8280846 645530 192038 453492 453492 OTHER MISCELLANEOUS 900099 19529 19529 19529 271727274 -13910814 42665209 42665209 41328384 41328384 4544768 4544768 1928334 1313608 354326 260400 69382376 47258757 12746230 9377389 1752493 1137472 295027 319994 9064877 5883642 1526046 1655189 5056965 3282269 851326 923370 799353 526011 108064 165278 235061 154681 31778 48602 858819 565143 116103 177573 4059876 4059876 190962 125663 25816 39483 14276467 9394577 1930024 2951866 6184624 2964761 816170 2403693 18094538 9531800 1979838 6582900 6313585 4154632 853528 1305425 8874288 6029595 1242672 1602021 7296935 4747531 1258507 1290897 6399479 4135437 1057956 1206086 596750 292444 266608 37698 MISCELLANEOUS 4865168 3070704 885368 909096 254769311 193107088 26345387 35316836 X 11780749 5786717 5994032 7141619 14966805 42601449 58353033 8633988 16707733 5813918 2768847 43265070 26528369 14702511 16736701 86639070 96515546 48953251 11144202 214485806 217192867 17799196 14820632 81859872 71699343 17304792 12592591 116963860 99112566 X 71640456 82002442 22847577 32998850 3033913 3079009 97521946 118080301 214485806 217192867 X 16957963 3584815 15577 X false true X true false X 282672072 279789664 302437152 283909984 285638088 1434446960 282672072 279789664 302437152 283909984 285638088 1434446960 213124363 1221322597 2705046 2260636 1203865 1891412 1565846 9626805 1502044 1974227 104879 56829 19529 3657508 1447731273 134627972 0.84360 0.83340 X PART II, LINE 10 GRANT TERM. & REFUND (YR 2011,2012) 3,321,237 OTHER MISC. REVENUE (YR 2011-2015) 336,271 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED true true false false true 157886 false true 125505 true 157031 true 418397 858819 false SCHEDULE C, PART II-B, LINE 1 LLS IS A MEMBER OF A NUMBER OF COALITIONS AND MEMBERSHIPS INCLUDING FRIENDS OF CANCER RESEARCH, ALLIANCE FOR A STRONGER FDA, ONE VOICE AGAINST CANCER, NATIONAL HEALTH COUNCIL, THE CANCER LEADERSHIP COUNCIL AND THE STATE ACCESS TO INNOVATIVE MEDICINES COALITION. SCHEDULE C, PART IV LLS PARTNERS WITH A NUMBER OF LOBBYING FIRMS WHO WORK WITH OUR PUBLIC POLICY STAFF TO CARRY OUT OUR LOBBYING OBJECTIVES. LLS MOBILIZES PATIENT- ADVOCATES AND VOLUNTEERS TO ENGAGE WITH THEIR FEDERAL AND STATE LEGISLATORS THROUGH DIGITAL ADVOCACY - SENDING LETTERS; SHARING THEIR PERSONAL STORIES; SIGNING PETITIONS; AND ENCOURAGING THEIR LEGISLATORS TO SUPPORT LLS' POLICY PRIORITIES. IN CONJUNCTION WITH LLS EMPLOYEES, PATIENT-ADVOCATES ALSO VISIT THEIR LEGISLATORS IN THEIR LOCAL OFFICES, IN WASHINGTON, DC AND IN STATE CAPITOLS TO FURTHER LLS' POLICY AGENDA. X false 6115645 45095 116288 -240000 -9060 6027967 6122698 218549 -221499 -4103 6115645 6027657 313872 -215000 -3831 6122698 6000186 482520 -450000 -5049 6027657 6059994 48916 -9992 6000186 0.51000 0.49000 false false 1211251 634183 577068 38235970 22872576 15363394 3817849 3021610 796239 16736701 FUND OF HEDGE FUNDS- OPERATING 9739180 F 457B PLAN 1405022 F FUND OF HEDGE FUNDS-ENDOWMENT F 11144202 X 295737491 3584815 11174900 9461935 24221650 271515841 190961 20472 211433 271727274 274565927 11174900 8702677 19877577 254688350 190961 -110000 80961 254769311 SCHEDULE D, PAGE 2, PART III, LINE 4 THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS. SCHEDULE D, PAGE 2, PART V, LINE 4 LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS. SCHEDULE D, PAGE 3, PART X LLS RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE TAX POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. LLS DID NOT RECOGNIZE ANY UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2016 AND 2015. SCHEDULE D, PAGE 4, PART XI, LINE 2D LLS CANADA REVENUE 8,899,624 PEARPOINT CANCER SUPPORT REVENUE 10,311 NET ASSETS TRANSFER 552,000 SCHEDULE D, PAGE 4, PART XI, LINE 4B PEARPOINT MANAGEMENT FEES 20,472 SCHEDULE D, PAGE 4, PART XII, LINE 2D LLS CANADA EXPENSES 8,653,353 PEARPOINT CANCER SUPPORT EXPENSES 49,324 SCHEDULE D, PAGE 4, PART XII, LINE 4B LLS CANADA FOREIGN CURRENCY ADJ -110,000 true CENTRAL AMERICA & CARIBBEAN 2 INVESTMENTS INVESTMENTS 5734913 EAST ASIA 3 RESEARCH FUNDING RESEARCH GRANTS 1940000 NORTH AMERICA 7 5 RESEARCH FUNDING RESEARCH GRANTS 1064385 EUROPE 8 RESEARCH FUNDING RESEARCH GRANTS 1540383 EUROPE 1 INVESTMENTS INVESTMENTS 1225325 7 19 7 19 11505006 11505006 EAST ASIA & PACIFIC RESEARCH GRANTS 1250000 CHECK FMV EAST ASIA & PACIFIC RESEARCH GRANTS 100000 CHECK FMV EAST ASIA & PACIFIC RESEARCH GRANTS 200000 CHECK FMV EUROPE RESEARCH GRANTS 65583 CHECK FMV EUROPE RESEARCH GRANTS 110000 CHECK FMV EUROPE RESEARCH GRANTS 200000 WIRE FMV EUROPE RESEARCH GRANTS 199800 WIRE FMV EUROPE RESEARCH GRANTS 200000 WIRE FMV EUROPE RESEARCH GRANTS 65000 WIRE FMV EUROPE RESEARCH GRANTS 200000 WIRE FMV EUROPE THERAPY ACCELERATION 500000 WIRE FMV NORTH AMERICA RESEARCH GRANTS 200000 WIRE FMV NORTH AMERICA RESEARCH GRANTS 200000 CHECK FMV NORTH AMERICA RESEARCH GRANTS 199980 WIRE FMV NORTH AMERICA RESEARCH GRANTS 65000 CHECK FMV EAST ASIA & PACIFIC RESEARCH GRANT 390000 CHECK FMV NORTH AMERICA RESEARCH GRANT 399405 CHECK FMV 17 true false true true false false SCHEDULE F, PAGE 1, PART I, LINE 2 FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. SCHEDULE F, PAGE 1, PART I, LINE 3 CENTRAL AMERICA & CARIBBEAN 0 5,734,913 EAST ASIA 1,940,000 0 NORTH AMERICA 1,064,385 0 EUROPE 1,540,383 0 EUROPE 0 1,225,325 X X X X X X true MAIL AMERICA COMMUNICATIONS INC 174 ELKTON FARM ROAD FOREST VA 24551 DIRECT MAI false 1642126 -1642126 THOMPSON HABIB & DENISON 80 HAYDEN AVENUE SUITE 300 LEXINGTON MA 02421 DIRECT MAI false 456932 -456932 COINSTAR 1800 114TH AVENUE SE BELLEVUE WA 98004 COIN COLLE false 407239 -407239 DONOR CARE CENTER INC 4345 STRAUSSSER ST NW NORTH CANTON OH 44720 TELEMARKET false 194253 -194253 THE HERITAGE COMPANY INC PO BOX 16325 LITTLE ROCK AR 722316325 DIRECT MAI false 70917 -70917 INFOCISION MANAGEMENT CORPORATION 325 SPRINSIDE DRIVE AKRON OH 44333 TELEMARKET false 54276 -54276 2825743 -2825743 All States LAKE TAHOE BIKE 3450905 3222877 228028 65572 211 53932 5 444194 DC LEUKEMIA BAL 3083245 1967862 1115383 6912 561055 325015 272400 6323 518 176011225 159886520 16124705 4511145 6832313 3296541 440177 8933167 182545375 165077259 17468116 4583629 7393579 3675488 712582 9383684 25748962 -8280846 false false 645530 2380 179806 9852 true 0.90000 645530 2380 179806 9852 192038 453492 AL DE DC NY OH OR PA TX IA true false false false 0.25000 0.75000 ROSEMARIE LOFFREDO 3 INTERNATIONAL DRIVE SUITE 200 RYE BROOK NY 10573 false SEE SCHEDULE G PART IV false SCHEDULE G, PAGE 2, PART III, LINE 9 TEXAS, IOWA SCHEDULE G, PART IV SCHEDULE G PART I, LINE 2B LLS USED MAIL AMERICA COMMUNICATIONS AND THOMPSON, HABIG & DENSION FOR ITS NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS. THESE PROGRAMS GENERATED GROSS RECEIPTS OF 19,208,525 DURING FISCAL YEAR 2016. LLS USED INFOCISION MANAGEMENT CORPORATION, COINSTAR AND DONOR CARE CENTER FOR ALL OF ITS OTHER FUNDRAISING EVENTS DURING THE FISCAL YEAR 2016. SCHEDULE G PART II - LINE 2 CONTRIBUTIONS REPRESENT THE CASH DONATIONS IN EXCESS OF THE FAIR MARKET VALUE OF BENEFITS PROVIDED TO THE DONOR. SCHEDULE G PART III - LINE 16 THE LEUKEMIA AND LYMPHOMA SOCIETY DOES NOT HAVE AN OVERALL MANAGER FOR GAMING ACTIVITIES. EACH GAMING EVENT IS MANAGED LOCALLY BY THE SPECIFIC CHAPTER STAFF. true ACETYLON PHARMACEUTICALS INC SEAPORT CTR 70 FARGO ST SUITE 205 BOSTON MA 022102138 263506788 1300000 FMV THERAPY ACCELERATION ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BELFER 1108 BRONX NY 10471 472209056 3 110000 ACCRUAL RESEARCH GRANT ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BELFER 1108 BRONX NY 10471 472209056 3 110000 ACCRUAL RESEARCH GRANT ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BELFER 1108 BRONX NY 10471 472209056 3 200000 ACCRUAL RESEARCH GRANT ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BELFER 1108 BRONX NY 10471 472209056 3 200000 ACCRUAL RESEARCH GRANT ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BELFER 1108 BRONX NY 10471 472209056 3 200000 ACCRUAL RESEARCH GRANT ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BELFER 1108 BRONX NY 10471 472209056 3 200000 ACCRUAL RESEARCH GRANT ARIZONA BOARD OF REGENTS UNIVERSIT PO BOX 210158 RM 510 TUCSON AZ 857210158 742652689 3 75000 ACCRUAL RESEARCH GRANT BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA MAIL STOP BCM-31 HOUSTON TX 77030 741613878 3 1250000 ACCRUAL RESEARCH GRANT BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA MAIL STOP BCM-31 HOUSTON TX 77030 741613878 3 200000 ACCRUAL RESEARCH GRANT BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA MAIL STOP BCM-31 HOUSTON TX 77030 741613878 3 200000 ACCRUAL RESEARCH GRANT BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA MAIL STOP BCM-310 HOUSTON TX 77030 741613878 3 100000 ACCRUAL RESEARCH GRANT BECKMAN RESEARCH INSTIT OF CITY OF 1500 DUARTE ROAD DUARTE CA 910103000 953432210 3 110000 ACCRUAL RESEARCH GRANT BECKMAN RESEARCH INSTIT OF CITY OF 1500 DUARTE ROAD DUARTE CA 910103000 953432210 3 110000 ACCRUAL RESEARCH GRANT BETH ISRAEL DEACONESS 330 BROOKLINE AVE BR-0259 BOSTON MA 02215 042103881 3 110000 ACCRUAL RESEARCH GRANT BETH ISRAEL DEACONESS 330 BROOKLINE AVE BR-0259 BOSTON MA 02215 042103881 3 55000 ACCRUAL RESEARCH GRANT BETH ISRAEL DEACONESS 330 BROOKLINE AVE BR-0259 BOSTON MA 02215 042103881 3 110000 ACCRUAL RESEARCH GRANT BOARD OF REGENTS U OF WISCONSIN SYS 21 N PARK ST SUITE 6401 MADISON WI 537151218 396006492 3 110000 ACCRUAL RESEARCH GRANT BOSTON CHILDREN'S HOSPITAL PO BOX 414413 BOSTON MA 022414413 042774441 3 55000 ACCRUAL RESEARCH GRANT BOSTON CHILDREN'S HOSPITAL PO BOX 414413 BOSTON MA 022414413 042774441 3 55000 ACCRUAL RESEARCH GRANT BOSTON CHILDREN'S HOSPITAL PO BOX 414413 BOSTON MA 022414413 042774441 3 110000 ACCRUAL RESEARCH GRANT BOSTON CHILDREN'S HOSPITAL PO BOX 414413 BOSTON MA 022414413 042774441 3 133333 ACCRUAL RESEARCH GRANT BRANDEIS UNIVERSITY 415 SOUTH ST WALTHAM MA 02454 042103552 3 55000 ACCRUAL RESEARCH GRANT BRIGHAM & WOMENS HOSPITAL PO BOX 3149 BOSTON MA 022413149 042312909 3 55000 ACCRUAL RESEARCH GRANT BRIGHAM & WOMENS HOSPITAL PO BOX 3149 BOSTON MA 022413149 042312909 3 110000 ACCRUAL RESEARCH GRANT BRIGHAM & WOMENS HOSPITAL PO BOX 3149 BOSTON MA 022413149 042312909 3 1250000 ACCRUAL RESEARCH GRANT BRIGHAM & WOMENS HOSPITAL PO BOX 3149 BOSTON MA 022413149 042312909 3 200000 ACCRUAL RESEARCH GRANT CALIFORNIA INSTITUTE OF TECHNOLOGY 1200 E CALIFORNIA BLVD MAIL CODE PASADENA CA 91125 951643307 3 55000 ACCRUAL RESEARCH GRANT CASE WESTERN RESERVE UNIV SCHOOL OF 10900 EUCLID AVENUE CLEVELAND OH 441067037 341018992 3 200000 ACCRUAL RESEARCH GRANT CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BOULEVARD 65-WIL 115 LOS ANGELES CA 90048 951644600 3 133333 ACCRUAL RESEARCH GRANT CHILDREN'S HOSPITAL CORPORATION 300 LONGWOOD AVENUE BOSTON MA 02115 042774441 3 55000 ACCRUAL RESEARCH GRANT CHILDREN'S HOSPITAL CORPORATION 300 LONGWOOD AVENUE BOSTON MA 02115 042774441 3 55000 ACCRUAL RESEARCH GRANT CHILDREN'S HOSPITAL LOS ANGELES 4650 SUNSET BLVD MAIL STOP 54 LOS ANGELES CA 90027 951690977 3 75000 ACCRUAL RESEARCH GRANT CHILDREN'S HOSPITAL LOS ANGELES 4650 SUNSET BLVD MAIL STOP 54 LOS ANGELES CA 90027 951690977 3 200000 ACCRUAL RESEARCH GRANT CHOP RESEARCH INSTITUTE LOCKBOX 1457 PO BOX 8500 PHILADELPHIA PA 191781457 231352166 3 110000 ACCRUAL RESEARCH GRANT CINCINNATI CHILDREN'S HOSPITAL MEDI 3333 BURNET AVENUE CINCINATTI OH 45229 310833936 3 110000 ACCRUAL RESEARCH GRANT CINCINNATI CHILDREN'S RESEARCH FOUN 3333 BURNET AVENUE CINCINNATI OH 45229 310833936 3 55000 ACCRUAL RESEARCH GRANT CINCINNATI CHILDREN'S RESEARCH FOUN 3333 BURNET AVENUE CINCINNATI OH 45229 310833936 3 200000 ACCRUAL RESEARCH GRANT CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND OH 44195 340714585 3 200000 ACCRUAL RESEARCH GRANT COLD SPRING HARBOR LABORATORY 1 BUNGTOWN ROAD PO BOX 100 COLD SPRING HARBOR NY 11724 112013303 3 110000 ACCRUAL RESEARCH GRANT COLUMBIA UNIVERSITY 615 WEST 131ST STREET - MAIL CODE 8 NEW YORK NY 10027 135598093 3 65000 ACCRUAL RESEARCH GRANT COLUMBIA UNIVERSITY 615 WEST 131ST STREET - MAIL CODE 8 NEW YORK NY 10027 135598093 3 55000 ACCRUAL RESEARCH GRANT COLUMBIA UNIVERSITY 615 WEST 131ST STREET - MAIL CODE 8 NEW YORK NY 10027 135598093 3 110000 ACCRUAL RESEARCH GRANT COLUMBIA UNIVERSITY 615 WEST 131ST STREET - MAIL CODE 8 NEW YORK NY 10027 135598093 3 110000 ACCRUAL RESEARCH GRANT COLUMBIA UNIVERSITY 615 WEST 131ST STREET - MAIL CODE 8 NEW YORK NY 10027 135598093 3 200000 ACCRUAL RESEARCH GRANT COLUMBIA UNIVERSITY 615 WEST 131ST STREET - MAIL CODE 8 NEW YORK NY 10027 135598093 3 200000 ACCRUAL RESEARCH GRANT COLUMBIA UNIVERSITY 615 WEST 131ST STREET - MAIL CODE 8 NEW YORK NY 10027 135598093 3 200000 ACCRUAL RESEARCH GRANT COLUMBIA UNIVERSITY 615 WEST 131ST STREET - MAIL CODE 8 NEW YORK NY 10027 135598093 3 200000 ACCRUAL RESEARCH GRANT COLUMBIA UNIVERSITY 615 WEST 131ST STREET NEW YORK NY 10027 135598093 3 150000 FMV RESEARCH GRANT CONSTELLATION PHARMACEUTICALS INC 215 FIRST STREET SUITE 200 CAMBRIDGE MA 02142 261741721 250000 FMV THERAPY ACCELERATION DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 55000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 55000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 110000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 55000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 55000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 55000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 110000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 110000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 110000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 110000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 110000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 109820 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 110000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 15477 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 65000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 1250000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 1000000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 200000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 200000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 200000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 75000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 75000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MAIL STOP BP4 BOSTON MA 02215 042263040 3 200000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE ROOM M557 BOSTON MA 022155450 042263040 3 138875 FMV THERAPY ACCELERATION DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE ROOM M557 BOSTON MA 022155450 042263040 3 111100 FMV THERAPY ACCELERATION DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE ROOM M557 BOSTON MA 022155450 042263040 3 55550 FMV THERAPY ACCELERATION DUKE UNIVERSITY MEDICAL CENTER 324 BLACKWLL STREET WASHINGTON BLD DURHAM NC 27708 560532129 3 200000 ACCRUAL RESEARCH GRANT DUKE UNIVERSITY MEDICAL CENTER 324 BLACKWLL STREET WASHINGTON BLD DURHAM NC 27708 560532129 3 200000 ACCRUAL RESEARCH GRANT EMORY UNIVERSITY 1599 CLIFTON RD NE 4TH FL 1599-0 ATLANTA GA 303224250 582137993 3 200000 ACCRUAL RESEARCH GRANT EMORY UNIVERSITY PO BOX 935084 ATLANTA GA 311935084 582137993 3 350000 FMV THERAPY ACCELERATION FRED HUTCHINSON CANCER RESEARCH CEN 1100 FAIRVIEW AVENUE NORTH J6-300 SEATTLE WA 981091024 237156071 3 110000 ACCRUAL RESEARCH GRANT FRED HUTCHINSON CANCER RESEARCH CEN 1100 FAIRVIEW AVENUE NORTH J6-300 SEATTLE WA 981091024 237156071 3 200000 ACCRUAL RESEARCH GRANT FRED HUTCHINSON CANCER RESEARCH CEN 1100 FAIRVIEW AVENUE NORTH J6-300 SEATTLE WA 981091024 237156071 3 200000 ACCRUAL RESEARCH GRANT ICAHN SCHOOL OF MEDICINE AT MOUNT S ONE GUSTAVE L LEVY PLACE BOX 350 NEW YORK NY 10029 136171197 3 110000 ACCRUAL RESEARCH GRANT ICAHN SCHOOL OF MEDICINE AT MOUNT S ONE GUSTAVE L LEVY PLACE BOX 350 NEW YORK NY 10029 136171197 3 110000 ACCRUAL RESEARCH GRANT ICAHN SCHOOL OF MEDICINE AT MOUNT S ONE GUSTAVE L LEVY PLACE BOX 350 NEW YORK NY 10029 136171197 3 110000 ACCRUAL RESEARCH GRANT ICAHN SCHOOL OF MEDICINE AT MOUNT S ONE GUSTAVE L LEVY PLACE BOX 350 NEW YORK NY 10029 136171197 3 300000 ACCRUAL RESEARCH GRANT INDIANA UNIVERSITY 509 E 3RD STREET BLOOMINGTON IN 474013654 356018940 3 110000 ACCRUAL RESEARCH GRANT INDIANA UNIVERSITY SCHOOL OF MEDICI 340 WEST 10TH STREET SUITE 6200 INDIANAPOLIS IN 462023082 356001673 3 75000 ACCRUAL RESEARCH GRANT IUPUI 980 INDIANA AVENUE INDIANAPOLIS IN 462022915 356001673 3 133333 ACCRUAL RESEARCH GRANT IWMF 6144 CLARK CENTER AVE SARASOTA FL 34238 541784426 3 125000 ACCRUAL RESEARCH GRANT JOHN HOPKINS UNIVERSITY JOHNS HOSPKINS UNIVERSITY CENTRAL L CHICAGO IL 60693 520595110 3 299238 FMV RESEARCH GRANT JOHNS HOPKINS UNIV 12529 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 520595110 3 55000 ACCRUAL RESEARCH GRANT JOHNS HOPKINS UNIV 12529 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 520595110 3 200000 ACCRUAL RESEARCH GRANT JOHNS HOPKINS UNIV 12529 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 520595110 3 200000 ACCRUAL RESEARCH GRANT JOHNS HOPKINS UNIVERSITY 12529 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 520595110 3 300000 FMV THERAPY ACCELERATION JOHNS HOPKINS UNIVERSITY CENTRAL LO 12529 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 520595110 3 250000 FMV THERAPY ACCELERATION KITE PHARMA INC 2225 COLORADO AVENUE SANTA MONICA CA 90404 271524986 1000000 FMV THERAPY ACCELERATION LA JOLLA INST FOR ALLERGY & IMMUNOL 9420 ATHENA CIRCLE LA JOLLA CA 92037 330328688 3 200000 ACCRUAL RESEARCH GRANT LELAND STANFORD JUNIOR UNIVERSITY STANFORD UNIVERSITY LOCKBOX PO BOX SAN FRANCISCO CA 94144 941156365 3 100000 ACCRUAL RESEARCH GRANT MASSACHUSETTS GENERAL HOSPITAL PO BOX 414876 BOSTON MA 022414876 041564655 3 55000 ACCRUAL RESEARCH GRANT MASSACHUSETTS GENERAL HOSPITAL PO BOX 414876 BOSTON MA 022414876 041564655 3 110000 ACCRUAL RESEARCH GRANT MASSACHUSETTS GENERAL HOSPITAL PO BOX 414876 BOSTON MA 022414876 041564655 3 65000 ACCRUAL RESEARCH GRANT MASSACHUSETTS GENERAL HOSPITAL PO BOX 414876 BOSTON MA 022414876 041564655 3 200000 ACCRUAL RESEARCH GRANT MASSACHUSETTS GENERAL HOSPITAL PO BOX 414876 BOSTON MA 022414876 041564655 3 200000 ACCRUAL RESEARCH GRANT MASSACHUSETTS GENERAL HOSPITAL MGH RESEARCH FINANCE PO BOX 414876 BOSTON MA 02241 041564655 3 75000 ACCRUAL RESEARCH GRANT MASSACHUSETTS INSTITUTE OF TECHNOLO 77 MASSACHUSETTS AVE CAMBRIDGE MA 02139 042103594 3 55000 ACCRUAL RESEARCH GRANT MAYO CLINIC ARIZONA MAYO CLINIC RESEARCH PO BOX 860334 MINNEAPOLIS MN 554860334 860800150 3 110000 ACCRUAL RESEARCH GRANT MAYO CLINIC ROCHESTER PO BOX 860334 MINNEAPOLIS MN 554860334 416011702 3 110000 ACCRUAL RESEARCH GRANT MAYO CLINIC ROCHESTER PO BOX 860334 MINNEAPOLIS MN 554860334 416011702 3 300000 ACCRUAL RESEARCH GRANT MAYO CLINIC ROCHESTER PO BOX 860334 MINNEAPOLIS MN 554860334 416011702 3 329938 FMV RESEARCH GRANT MD ANDERSON CANCER CENTER PO BOX 4390 HOUSTON TX 772104390 746001118 3 110000 ACCRUAL RESEARCH GRANT MD ANDERSON CANCER CENTER PO BOX 4390 HOUSTON TX 772104390 746001118 3 110000 ACCRUAL RESEARCH GRANT MD ANDERSON CANCER CENTER PO BOX 4390 HOUSTON TX 772104390 746001118 3 200000 ACCRUAL RESEARCH GRANT MD ANDERSON CANCER CENTER PO BOX 4390 HOUSTON TX 772104390 746001118 3 200000 ACCRUAL RESEARCH GRANT MD ANDERSON CANCER CENTER PO BOX 4390 HOUSTON TX 772104390 746001118 3 200000 ACCRUAL RESEARCH GRANT MD ANDERSON CANCER CENTER PO BOX 4390 HOUSTON TX 77210 746001118 3 400000 FMV RESEARCH GRANT MEMORIAL SLOAN KETTERING CANCER CEN PO BOX 026338 NEW YORK NY 10087 131924236 3 55000 ACCRUAL RESEARCH GRANT MEMORIAL SLOAN KETTERING CANCER CEN PO BOX 026338 NEW YORK NY 10087 131924236 3 110000 ACCRUAL RESEARCH GRANT MEMORIAL SLOAN KETTERING CANCER CEN PO BOX 026338 NEW YORK NY 10087 131924236 3 110000 ACCRUAL RESEARCH GRANT MEMORIAL SLOAN KETTERING CANCER CEN PO BOX 026338 NEW YORK NY 10087 131924236 3 65000 ACCRUAL RESEARCH GRANT MEMORIAL SLOAN KETTERING CANCER CEN PO BOX 026338 NEW YORK NY 10087 131924236 3 55000 ACCRUAL RESEARCH GRANT MEMORIAL SLOAN KETTERING CANCER CEN PO BOX 026338 NEW YORK NY 10087 131924236 3 110000 ACCRUAL RESEARCH GRANT MEMORIAL SLOAN KETTERING CANCER CEN PO BOX 026338 NEW YORK NY 10087 131924236 3 110000 ACCRUAL RESEARCH GRANT MEMORIAL SLOAN KETTERING CANCER CEN PO BOX 026338 NEW YORK NY 10087 131924236 3 110000 ACCRUAL RESEARCH GRANT MEMORIAL SLOAN KETTERING CANCER CEN PO BOX 026338 NEW YORK NY 10087 131924236 3 110000 ACCRUAL RESEARCH GRANT MEMORIAL SLOAN KETTERING CANCER CEN PO BOX 026338 NEW YORK NY 10087 131924236 3 110000 ACCRUAL RESEARCH GRANT MEMORIAL SLOAN KETTERING CANCER CEN PO BOX 026338 NEW YORK NY 10087 131924236 3 110000 ACCRUAL RESEARCH GRANT MEMORIAL SLOAN KETTERING CANCER CEN PO BOX 026338 NEW YORK NY 10087 131924236 3 65000 ACCRUAL RESEARCH GRANT MEMORIAL SLOAN KETTERING CANCER CEN PO BOX 026338 NEW YORK NY 10087 131924236 3 192404 ACCRUAL RESEARCH GRANT MEMORIAL SLOAN KETTERING CANCER CEN PO BOX 026338 NEW YORK NY 10087 131924236 3 200000 ACCRUAL RESEARCH GRANT MOFFITT CANCER CENTER PO BOX 742801 ATLANTA GA 303742801 593238634 3 200000 ACCRUAL RESEARCH GRANT MPNRF 180 N MICHIGAN AVENUE SUITE 1870 CHICAGO IL 60601 364330967 3 100000 ACCRUAL RESEARCH GRANT NEW YORK UNIVERSITY 665 BROADWAY SUITE 801 NEW YORK NY 100122331 135562308 3 75000 ACCRUAL RESEARCH GRANT NORTHWESTERN UNIVERSITY 633 CLARK - ROOM G547 EVANSTON IL 60208 362167817 3 133333 ACCRUAL RESEARCH GRANT NYU MEDICAL CENTER 1 PARK AVENUE 6TH FLOOR NEW YORK NY 10016 135562308 3 55000 ACCRUAL RESEARCH GRANT NYU SCHOOL OF MEDICINE PO BOX 415026 BOSTON MA 022414150 135562308 3 65000 ACCRUAL RESEARCH GRANT NYU SCHOOL OF MEDICINE PO BOX 415026 BOSTON MA 022414150 135562308 3 1250000 ACCRUAL RESEARCH GRANT NYU SCHOOL OF MEDICINE PO BOX 415026 BOSTON MA 022414150 135562308 3 200000 ACCRUAL RESEARCH GRANT NYU SCHOOL OF MEDICINE PO BOX 415026 BOSTON MA 022414150 135562308 3 200000 ACCRUAL RESEARCH GRANT OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD PORTLAND OR 972393098 237083114 3 1111000 FMV THERAPY ACCELERATION OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD PORTLAND OR 972393098 237083114 3 1111000 FMV THERAPY ACCELERATION PENN MEDICINE 295 JOHN MORGAN BUILDING 3620 HAMI PHILADELPHIA PA 19104 231352685 3 110000 ACCRUAL RESEARCH GRANT PRESIDENT & FELLOWS OF HARVARD COLL PO BOX 415649 BOSTON MA 024415649 042103580 3 55000 ACCRUAL RESEARCH GRANT REGENTS OF THE UNIVERSITY OF MICHIG BOX 223131 PITTSBURGH PA 152512131 386006309 3 110000 ACCRUAL RESEARCH GRANT REGENTS OF THE UNIVERSITY OF MICHIG BOX 223131 PITTSBURGH PA 152512131 386006309 3 106384 ACCRUAL RESEARCH GRANT REGENTS OF THE UNIVERSITY OF MICHIG BOX 223131 PITTSBURGH PA 152512131 386006309 3 110000 ACCRUAL RESEARCH GRANT REGENTS OF THE UNIVERSITY OF MICHIG BOX 223131 PITTSBURGH PA 152512131 386006309 3 110000 ACCRUAL RESEARCH GRANT REGENTS OF THE UNIVERSITY OF MICHIG BOX 223131 PITTSBURGH PA 152512131 386006309 3 300000 ACCRUAL RESEARCH GRANT REGENTS OF THE UNIVERSITY OF MICHIG BOX 223131 PITTSBURGH PA 152512131 386006309 3 200000 ACCRUAL RESEARCH GRANT REGENTS OF THE UNIVERSITY OF MICHIG BOX 223131 PITTSBURGH PA 152512131 386006309 3 200000 ACCRUAL RESEARCH GRANT REGENTS OF THE UNIVERSITY OF MICHIG BOX 223131 PITTSBURGH PA 152512131 386006309 3 300000 ACCRUAL RESEARCH GRANT REGENTS OF THE UNIVERSITY OF MICHIG BOX 223131 PITTSBURGH PA 152512131 386006309 3 300000 ACCRUAL RESEARCH GRANT REGENTS OF THE UNIVERSITY OF MICHIG PO BOX 223131 PITTSBURGH PA 152512131 386006309 3 349925 FMV RESEARCH GRANT RESEARCH FOUNDATION SUNY 750 E ADAMS STREET ROOM 209 CAB SYRACUSE NY 13210 141368361 3 110000 ACCRUAL RESEARCH GRANT ST JUDE CHILDREN'S RESEARCH HOSPIT PO BOX 1000 DEPT 949 MEMPHIS TN 381480949 620646012 3 65000 ACCRUAL RESEARCH GRANT ST JUDE CHILDREN'S RESEARCH HOSPIT PO BOX 1000 DEPT 949 MEMPHIS TN 381480949 620646012 3 200000 ACCRUAL RESEARCH GRANT STANFORD UNIVERSITY PO BOX 44253 SAN FRANCISCO CA 941444253 941156365 3 55000 ACCRUAL RESEARCH GRANT STANFORD UNIVERSITY PO BOX 44253 SAN FRANCISCO CA 941444253 941156365 3 65000 ACCRUAL RESEARCH GRANT STANFORD UNIVERSITY PO BOX 44253 SAN FRANCISCO CA 941444253 941156365 3 55000 ACCRUAL RESEARCH GRANT STANFORD UNIVERSITY PO BOX 44253 SAN FRANCISCO CA 941444253 941156365 3 110000 ACCRUAL RESEARCH GRANT STANFORD UNIVERSITY PO BOX 44253 SAN FRANCISCO CA 941444253 941156365 3 65000 ACCRUAL RESEARCH GRANT STEMLINE THERAPEUTICS INC 750 LEXINGTON AVENUE 11TH FLOOR NEW YORK NY 10022 450522567 500000 FMV THERAPY ACCELERATION TEMPLE UNIVERSITY PO BOX 824242 PHILADELPHIA PA 191824242 231365971 3 400000 FMV RESEARCH GRANT THE OHIO STATE UNIVERSITY 1960 KENNY ROAD COLUMBUS OH 43210 316025986 3 110000 ACCRUAL RESEARCH GRANT THE OHIO STATE UNIVERSITY 1960 KENNY ROAD OFFICE OF SPONSORE COLUMBUS OH 43210 316025986 3 200000 ACCRUAL RESEARCH GRANT THE SCRIPPS RESEARCH INSTITUTE 10550 NORTH TORREY PINES ROAD TPC- LA JOLLA CA 92037 330435954 3 55000 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF ARIZONA 512 PO BOX 210066 TUCSON AZ 857210066 742652689 3 200000 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF CHICAGO 6030 S ELLIS AVE ROOM 114 ED-11 CHICAGO IL 60637 362177139 3 55000 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF CHICAGO 6030 S ELLIS AVE ROOM 114 ED-11 CHICAGO IL 60637 362177139 3 200000 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF CHICAGO 6030 S ELLIS AVE ROOM 114 ED-11 CHICAGO IL 60637 362177139 3 200000 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF CHICAGO 5841 S MARYLAND AVE MC6092 CHICAGO IL 60637 362177139 3 200000 ACCRUAL RESEARCH GRANT TUFTS MEDICAL CENTER 800 WASHINGTON STREET 453 BOSTON MA 02111 042103634 3 200000 ACCRUAL RESEARCH GRANT UC SAN DIEGO - HEALTH SCIENCES 9500 GILMAN DRIVE MC 0009 LA JOLLA CA 920930009 952872494 3 55000 ACCRUAL RESEARCH GRANT UNC AT CHAPEL HILL PO BOX 402420 ATLANTA GA 303842420 566001393 3 65000 ACCRUAL RESEARCH GRANT UNC AT CHAPEL HILL PO BOX 402420 ATLANTA GA 303842420 566001393 3 199541 ACCRUAL RESEARCH GRANT UNIV OF TEXAS HEALTH SCIENCE CENTER MAIL CODE 78287703 FLOYD CURL DRIVE SAN ANTONIO TX 782293900 741586031 3 200000 ACCRUAL RESEARCH GRANT UNIV OF MASSACHUSETTS 55 LAKE AVENUE NORTH WORCESTER MA 016550002 043167352 3 65000 ACCRUAL RESEARCH GRANT UNIV OF MASSACHUSETTS 55 LAKE AVENUE NORTH WORCESTER MA 016550002 043167352 3 55000 ACCRUAL RESEARCH GRANT UNIV OF MASSACHUSETTS 55 LAKE AVENUE NORTH WORCESTER MA 016550002 043167352 3 110000 ACCRUAL RESEARCH GRANT UNIV OF MASSACHUSETTS 55 LAKE AVENUE NORTH WORCESTER MA 016550002 043167352 3 110000 ACCRUAL RESEARCH GRANT UNIV OF MASSACHUSETTS 55 LAKE AVENUE NORTH WORCESTER MA 016550002 043167352 3 110000 ACCRUAL RESEARCH GRANT UNIV OF MASSACHUSETTS 55 LAKE AVENUE NORTH WORCESTER MA 016550002 043167352 3 200000 ACCRUAL RESEARCH GRANT UNIVERSITY OF ALABAMA AT BIRMINGHAM 1530 3RD AVENUE SOUTH SUITE 1170 BIRMINGHAM AL 352940111 636005396 3 110000 ACCRUAL RESEARCH GRANT UNIVERSITY OF ALABAMA AT BIRMINGHAM 1530 3RD AVENUE SOUTH SUITE 1170 BIRMINGHAM AL 352940111 636005396 3 300000 ACCRUAL RESEARCH GRANT UNIVERSITY OF ALABAMA AT BIRMINGHAM 1530 3RD AVENUE SOUTH SUITE 1170 BIRMINGHAM AL 352940111 636005396 3 200000 ACCRUAL RESEARCH GRANT UNIVERSITY OF ALABAMA AT BIRMINGHAM 1530 3RD AVENUE SOUTH SUITE 1170 BIRMINGHAM AL 352940111 636005396 3 200000 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA LOS ANGEL 11000 KINROSS AVE SUITE 102 LOS ANGELES CA 90095 956006143 3 55000 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0009 LA JOLLA CA 920930009 956006144 3 110000 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0009 LA JOLLA CA 920930009 956006144 3 110000 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0009 LA JOLLA CA 920930009 956006144 3 1250000 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0009 LA JOLLA CA 920930009 956006144 3 75000 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA SAN FRANC 1855 FOLSOM STREET SUITE 425 SAN FRANCISCO CA 94143 946036493 3 55000 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA SAN FRANC 1855 FOLSOM STREET SUITE 425 SAN FRANCISCO CA 94143 946036493 3 55000 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA SAN FRANC 1855 FOLSOM STREET SUITE 425 SAN FRANCISCO CA 94143 946036493 3 110000 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA SAN FRANC 1855 FOLSOM STREET SUITE 425 SAN FRANCISCO CA 94143 946036493 3 110000 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA SAN FRANC 1855 FOLSOM STREET SUITE 425 SAN FRANCISCO CA 94143 946036493 3 110000 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA SAN FRANC 1855 FOLSOM STREET SUITE 425 SAN FRANCISCO CA 94143 946036493 3 65000 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA SAN FRANC 1855 FOLSOM STREET SUITE 425 SAN FRANCISCO CA 94143 946036493 3 200000 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA SAN FRANC 1855 FOLSOM STREET SUITE 425 SAN FRANCISCO CA 94143 946036493 3 75000 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA SAN FRANC CGA BOX 0897 SAN FRANCISCO CA 94143 946036493 3 55000 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA SAN FRANC CGA BOX 0897 SAN FRANCISCO CA 94143 946036493 3 55000 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA SAN FRANC CGA BOX 0897 SAN FRANCISCO CA 94143 946036493 3 55000 ACCRUAL RESEARCH GRANT UNIVERSITY OF CONNECTICUT HEALTH CE 263 FARMINGTON AVENUE FARMINGTON CT 060305335 521725543 150000 FMV RESEARCH GRANT UNIVERSITY OF FLORIDA 33 TIGERT HALL P O BOX 113001 GAINESVILLE FL 326113001 596002052 3 109169 ACCRUAL RESEARCH GRANT UNIVERSITY OF FLORIDA 33 TIGERT HALL P O BOX 113001 GAINESVILLE FL 326113001 596002052 3 1250000 ACCRUAL RESEARCH GRANT UNIVERSITY OF IOWA GILMORE HALL UNIVERSITY OF IOWA IOWA CITY IA 52242 426004813 3 200000 ACCRUAL RESEARCH GRANT UNIVERSITY OF MARYLAND AT BALTIMORE PO BOX 41428 BALTIMORE MD 212036428 526002033 3 200000 ACCRUAL RESEARCH GRANT UNIVERSITY OF MINNESOTA 450 MCNAMARA ALUMNI CENTER 200 OAK MINNEAPOLIS MN 55455 416042488 3 75000 ACCRUAL RESEARCH GRANT UNIVERSITY OF MINNESOTA TWIN CITIE 450 MCNAMARA ALUMNI CENTER MINNEAPOLIS MN 55455 416007513 3 200000 ACCRUAL RESEARCH GRANT UNIVERSITY OF PENNSYLVANIA PO BOX 785541 PHILADELPHIA PA 191785541 231352685 3 55000 ACCRUAL RESEARCH GRANT UNIVERSITY OF PENNSYLVANIA PO BOX 785541 PHILADELPHIA PA 191785541 231352685 3 55000 ACCRUAL RESEARCH GRANT UNIVERSITY OF PENNSYLVANIA PO BOX 785541 PHILADELPHIA PA 191785541 231352685 3 1250000 ACCRUAL RESEARCH GRANT UNIVERSITY OF PENNSYLVANIA PO BOX 785541 PHILADELPHIA PA 191785541 231352685 3 200000 ACCRUAL RESEARCH GRANT UNIVERSITY OF SOUTH CAROLINA 901 SUMTER STREET 5TH FLOOR USC R COLUMBIA SC 29208 576001153 3 25000 ACCRUAL RESEARCH GRANT UNIVERSITY OF SOUTHERN CALIFORNIA 2250 ALCAZAR STREET CONTRACTS GR LOS ANGELES CA 900742095 951642394 3 65000 ACCRUAL RESEARCH GRANT UNIVERSITY OF TEXAS PO BOX 4390 HOUSTON TX 772104390 300710145 3 1000000 FMV THERAPY ACCELERATION UT SOUTHWESTERN MEDICAL CENTER PO BOX 841753 DALLAS TX 752841753 756002868 3 110000 ACCRUAL RESEARCH GRANT VALOR BIOTHERAPEUTICS PO BOX 15922 COLLEGE STATION TX 77841 461883738 450000 FMV THERAPY ACCELERATION VALOR BIOTHERAPEUTICS PO BOX 15922 COLLEGE STATION TX 77841 461883738 400000 FMV THERAPY ACCELERATION VANDERBILT UNIVERSITY MEDICAL CENTE DEPT 1236 PO BOX 121236 DALLAS TX 753121236 620476822 3 110000 ACCRUAL RESEARCH GRANT VIRGINIA COMMONWEALTH UNIVERSITY PO BOX 843039 RICHMOND VA 232843039 012201761 3 200000 ACCRUAL RESEARCH GRANT WASHINGTON UNIVERSITY SCHOOL OF MED 700 ROSEDALE AVENUE CAMPUS BOX 1034 ST LOUIS MO 631121408 430653611 3 110000 ACCRUAL RESEARCH GRANT WASHINGTON UNIVERSITY SCHOOL OF MED 700 ROSEDALE AVENUE CAMPUS BOX 1034 ST LOUIS MO 631121408 430653611 3 200000 ACCRUAL RESEARCH GRANT WEILL CORNELL MEDICAL COLLEGE 575 LEXINGTON AVE 9TH FL NEW YORK NY 10022 131623978 3 110000 ACCRUAL RESEARCH GRANT WEILL CORNELL MEDICAL COLLEGE 575 LEXINGTON AVE 9TH FL NEW YORK NY 10022 131623978 3 200000 ACCRUAL RESEARCH GRANT WEILL CORNELL MEDICAL COLLEGE 575 LEXINGTON AVE 9TH FL NEW YORK NY 10022 131623978 3 200000 ACCRUAL RESEARCH GRANT WEILL CORNELL MEDICAL COLLEGE 575 LEXINGTON AVE 9TH FL NEW YORK NY 10022 131623978 3 200000 ACCRUAL RESEARCH GRANT WEILL CORNELL MEDICAL COLLEGE 575 LEXINGTON AVE 9TH FL NEW YORK NY 10022 131623978 3 400000 ACCRUAL RESEARCH GRANT WEILL CORNELL MEDICAL COLLEGE 575 LEXINGTON AVE 9TH FL NEW YORK NY 10022 131623978 3 390284 FMV RESEARCH GRANT WEILL MEDICAL COLLEGE OF CORNELL 575 LEXINGTON AVE 9TH FL NEW YORK NY 10022 131623978 3 300000 FMV THERAPY ACCELERATION WHITEHEAD INSTITUTE FOR BIOMEDICAL 9 CAMBRIDGE CENTER CAMBRIDGE MA 021421479 061043412 3 106749 ACCRUAL RESEARCH GRANT YALE UNIVERSITY PO BOX 208327 NEW HAVEN CT 065208327 060646973 3 55000 ACCRUAL RESEARCH GRANT YALE UNIVERSITY PO BOX 208327 NEW HAVEN CT 065208327 060646973 3 75000 ACCRUAL RESEARCH GRANT YALE UNIVERSITY PO BOX 208327 NEW HAVEN CT 065208327 060646973 3 55000 ACCRUAL RESEARCH GRANT YALE UNIVERSITY PO BOX 208327 NEW HAVEN CT 065208327 060646973 3 200000 ACCRUAL RESEARCH GRANT 84 6 COPAY ASSISTANCE CLL 2064 3386407 COPAY ASSISTANCE LYMPHOMA 6770 10530020 COPAY ASSISTANCE MDS 1382 3097062 COPAY ASSISTANCE MYELOMA 6191 20393154 COPAY ASSISTANCE MANTEL 647 1633028 COPAY ASSISTANCE ALL 76 159372 COPAY ASSISTANCE WALDENST 443 1133194 PATIENT TRAVEL ASSISTNCE 1587 1298739 PATIENT FINANCIAL AID 260 12827 SCHEDULE I, PAGE 1, PART I, LINE 2 FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. PATIENT FINANCIAL AID: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR MANY EXPENSES RELATED TO THEIR TREATMENT. SOMETIMES PATIENTS HAVE TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE TREATMENT EXPENSES. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS HAS ESTABLISHED A PATIENT FINANCIAL AID PROGRAM THAT PROVIDES APPLICANTS, WHO RESIDE IN THE US AND HAVE A BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. CO-PAY ASSISTANCE: PATIENT APPLICATIONS ARE PROCESSED ON A FIRST COME, FIRST SERVED BASIS. ELIGIBLE PATIENTS MUST RESIDE IN THE UNITED STATES OR PUERTO RICO, HAVE A PROGRAM COVERED BLOOD CANCER DIAGNOSIS CONFIRMED BY A PHYSICIAN, MAINTAIN MEDICAL/PRESCRIPTION INSURANCE AND HAVE HOUSEHOLD INCOME AT OR BELOW 500% OF THE US FEDERAL POVERTY LEVEL AS ADJUSTED BY HOUSEHOLD SIZE AND COST OF LIVING INDEX. PATIENTS MUST PROVIDE PROOF OF INSURANCE AND INCOME. QUALIFYING PATIENTS ARE APPROVED FOR A TWELVE MONTH COVERAGE PERIOD. PATIENT TRAVEL ASSISTANCE: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR TRANSPORTATION TO GET TO THEIR PROVIDERS, E.G. DOCTORS, HOSPITALS, TRANSPLANT CENTERS, AND RESEARCH OR CLINICAL TRIAL CENTERS. SOMETIMES PATIENTS HAVE TO TRAVEL OUT-OF-STATE TO GET THEIR PRESCRIBED AND RECOMMENDED TREATMENTS, OFTENTIMES RESULTING IN PATIENTS HAVING TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS ESTABLISHED THE TRAVEL ASSISTANCE PROGRAM WHICH PROVIDES APPLICANTS, WHO ARE US CITIZENS OR PERMANENT RESIDENTS, HAVE AN ANNUAL INCOME AT OR BELOW 500% OF THE FEDERAL POVERTY LEVEL (FPL) AND HAVE A CONFIRMED BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. X X X X X true true false false false false false true false LOUIS J DEGENNARO PRESIDENT & CEO 480095 30954 31500 23678 566227 ROSEMARIE A LOFFREDO EVP - CAO & CFO 302398 22745 12775 13781 351699 GORDON MILLER JR SVP FINANCE 235416 20830 761 15788 28464 301259 MARK ROITHMAYR EVP CHIEF REL OFFICE 348332 12212 15758 31896 408198 ANDREW S COCCARI EVP CHIEF PROD OFFIC 150729 690 26842 178261 CLAUDE E EDKINS SVP CHIEF INFO OFFIC 211704 96643 13491 24634 346472 LEE M GREENBERGER SVP CHIEF SCIEN OFFI 281965 6470 11351 31446 331232 NANCY HALLBERG SVP CHIEF MARK OFFIC 223534 3191 3998 22799 253522 JAMES A MASSARA VP APP & TRAIN. SUPP 154434 70518 9727 25449 260128 OSMAN MAZHAR VP PLATFORM SERVICES 151628 71893 9439 25255 258215 JEFFREY COMO-TERM DEC2014 CHIEF INFORM.OFFICER 130452 130452 GEORGE J OMIROS-TERM APR15 EVP-CHIEF CAMP&FIELD 120687 364888 3045 6853 495473 GABRIELLE URQUHART-TERM JUN15 REGIONAL VP 119184 67542 5838 4828 197392 JOHN E WALTER - TERM FEB14 PRESIDENT & CEO 43333 102994 146327 SCHEDULE J, PAGE 1, PART I, LINE 4 LOUIS J. DEGENNARO 0 1 0 JEFFREY COMO-TERM DEC2014 130,452 0 0 GEORGE J. OMIROS-TERM APR15 363,758 0 0 GABRIELLE URQUHART-TERM JUN15 66,554 0 0 JOHN E. WALTER - TERM FEB14 102,994 0 0 SCHEDULE J, PAGE 1, PART I, LINE 7 PART I, LINE 7 - NON-FIXED PAYMENTS PROVIDED BONUSES WERE PAID BASED ON THE ACHIEVEMENT OF THE EMPLOYEE INDIVIDUAL PERFORMANCE. BONUSES WERE CAPPED ACCORDING TO LLS'S POLICY. THESE AMOUNTS ARE REPORTED ON SCHEDULE J PART II, COLUMN (B)(II). X 153 1349813 MARKET VALUE X 62 X PRINTED ITEMS 15 X VARIOUS 38 false true false SCHEDULE M, PAGE 2, PART II PART I, COLUMN (B) LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS. PART I, LINE 33 - EXPLANATION FOR NOT REPORTING REVENUE LLS ONLY RECORDS DONATED SECURITIES AS REVENUE. ALL OTHER ITEMS FOR WHICH COLUMN A IS CHECKED ARE NOT RECORDED AS REVENUE OR EXPENSE BECAUSE THEY WOULD NOT HAVE BEEN PURCHASED HAD THEY NOT BEEN DONATED, AND ARE IMMATERIAL IN AMOUNT RELATIVE TO THE STATEMENTS OF LLS. FORM 990, PAGE 2, PART III, LINE 4A WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2016, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 5 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 47 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, AND, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGIANST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECIEVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2016, FOR THE FIFTH YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOLENT LYMPHOMA PATIENTS - DEFINE GENETIC/MOLECULAR PREDISPOSITIONS TO LONG-TERM AND LATE-TERM EFFECTS ASSOCIATED WITH STANDARD THERAPIES IN PEDIATRIC ALL AND APPLY THIS INFORMATION TO IMPROVE PATIENT OUTCOMES. THE THERAPY ACCELERATION PROGRAM THIS STRATEGIC INITIATIVE WAS LAUNCHED IN 2007 TO MOVE NEW TREATMENTS AND DIAGNOSTICS THROUGH PRECLINICAL DEVELOPMENT AND CLINICAL TRIALS, FASTER. USING MILESTONE-DRIVEN CONTRACTS AND WORKING IN CONCERT WITH ACADEMIC INVESTIGATORS, MEDICAL CENTERS AND COMPANIES, LLS IS FURTHER BRIDGING THE GAP BETWEEN DISCOVERY AND HUMAN APPLICATIONS TO INCREASE THE LIKELIHOOD THAT NOVEL, POSSIBLY BREAKTHROUGH, TREATMENTS WILL BE AVAILABLE TO PATIENTS AS SOON A FORM 990, PAGE 2, PART III, LINE 4B SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PRINT PUBLICATIONS AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES DISEASE AND SUPPORT BOOKLETS AND FACT SHEETS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. EACH YEAR, LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. - 615,479 FREE PRINTED DISEASE AND SUPPORT BOOKLETS, 5,498 DISEASE-FOCUSED FACT SHEETS, AND 141 DVDS WERE ORDERED IN 2016. FINANCIAL ASSISTANCE IN 2016, A COMBINED 40,835,972 WAS DISBURSED TO PATIENTS THROUGH THE CO-PAY ASSISTANCE PROGRAMS (40,029,645) AND THE LLS NATIONAL PATIENT TRAVEL ASSISTANCE PROGRAM, (793,500), AND LLS FINANCIAL ASSISTANCE PROGRAM (12,827). CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2016, 40,029,645 WAS PROVIDED TO PATIENTS THROUGH THE LLS CO-PAY ASSISTANCE PROGRAM. - 18,155 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2016. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM THE SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS WITH TRAVEL AND LODGING EXPENSES RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. TRAVEL ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY. IN 2016, 793,500 WAS PROVIDED TO PATIENTS THROUGH THE LLS SUSAN LANG TRAVEL PROGRAM 1,587 PATIENTS RECEIVED LLS TRAVEL ASSISTANCE IN 2016 FINANCIAL ASSISTANCE PROGRAM FOR CML PATIENTS (PCR PROGRAM) THE FINANCIAL ASSISTANCE PROGRAM FOR CML PATIENTS SUPPORTS QUALIFYING PATIENTS WITH OUT OF POCKET EXPENSES RELATED TO THEIR ROUTINE POLYMERASE CHAIN REACTION (PCR) EXAM. IN 2016, 12,827 WAS PROVIDED TO PATIENTS THROUGH THE PCR PROGRAM 260 PATIENTS RECEIVED LLS PCR ASSISTANCE IN 2016 COMMUNITY PROGRAMS SERVICES ARE PROVIDED IN COMMUNITIES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS BY STAFF (PATIENT ACCESS MANAGERS) AND TRAINED VOLUNTEERS WHO HAVE SPECIFIC SUPPORT AND OUTREACH ROLES. STAFF ARE HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING, PUBLIC HEALTH OR SOCIAL WORK; VOLUNTEERS ARE TYPICALLY PATIENTS OR CAREGIVERS WHO UNDERGO RIGOROUS BACKGROUND CHECKS AND TRAINING. STAFF AND VOLUNTEERS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS, AND PROVIDE COMMUNITY-BASED OUTREACH, EDUCATION, AND SUPPORT IN A VARIETY OF FORMS. LOCAL PATIENT EDUCATION PROGRAMS: IN FY 2016 WE CONDUCTED 43 LOCAL PATIENT EDUCATION PROGRAMS TO 1,893 ATTENDEES. THIRTY-SIX WERE PROGRAMS THAT COVERED DISEASE SPECIFIC TOPICS, SURVIVORSHIP ISSUES, AND/OR EDUCATION ABOUT CANCER CLINICAL TRIALS AND MAKING TREATMENT DECISIONS. OF THESE 36, 12 WERE LOCATED IN AND WERE SPECIFICALLY TAILORED TO UNDERSERVED COMMUNITIES, ESPECIALLY RACIAL AND ETHNIC MINORITY GROUPS AND OLDER ADULTS. SEVEN PROGRAMS WERE FOCUSED ON THE DIAGNOSIS AND TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS OR MPN. REGIONAL BLOOD CANCER CONFERENCES: LLS WORKS TO ELEVATE OUR VISIBILITY IN COMMUNITIES WE SERVE BY HOSTING LARGER-SCALE CONFERENCES, GEARED FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. THESE EVENTS ARE A CATALYST FOR BRINGING MANY DEDICATED PEOPLE TOGETHER TO FOCUS ON BLOOD CANCER AWARENESS, INFORMATION AND THE LATEST ADVANCES IN MEDICAL SCIENCE. THEY ARE DESIGNED FOR PATIENTS AND CAREGIVERS BUT ARE ATTENDED BY SOME LOCAL HEALTHCARE PROFESSIONALS (NURSES AND SOCIAL WORKERS) AS WELL. IN 2016, 16 BCC CONFERENCES WERE HELD WITH 4,805 ATTENDEES LLS COMMUNITY THE ONLINE "LLS COMMUNITY" WAS LAUNCHED ON FEBRUARY 1, 2016. IT WAS DESIGNED TO PROVIDE A WAY FOR PATIENTS AND CAREGIVERS TO: 1) BECOME PART OF A SOCIAL NETWORK TO CONNECT WITH PATIENTS AND CAREGIVERS IN SIMILAR SITUATIONS AND BECOME EMPOWERED; 2) PROVIDE INFORMATION ABOUT ONESELF AND ONE'S DISEASE, TO BECOME PART OF THE RESEARCH TO CURE BLOOD CANCERS; AND 3) GAIN THE LATEST INFORMATION ABOUT ONE'S DISEASE, LEARN ABOUT SURVIVORSHIP ISSUES, AND ABOUT CLINICAL TRIALS. BY THE END OF FY 2016, THERE WERE APPROXIMATELY 2,500 COMMUNITY MEMBERS AND 15,000 RESPONSES TO THE "QUESTIONS OF THE DAY," AS WELL AS CLOSE TO 4,000 COMMENTS POSTED BY USERS FAMILY SUPPORT GROUPS: THROUGHOUT THE US, IN 2016, LLS SUPPORTED OR HOSTED 204 REGISTERED FAMILY SUPPORT GROUP MEETINGS FOR PATIENTS AND THEIR FAMILIES. GROUPS ARE GUIDED BY ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. LLS SUPPORT GROUPS ARE THE PERFECT PLACE TO TALK WITH OTHER PEOPLE AFFECTED BY BLOOD CANCERS, INCLUDING PATIENTS, FAMILY MEMBERS AND CAREGIVERS. THE GROUPS PROVIDE MUTUAL SUPPORT AND OFFER THE OPPORTUNITY TO DISCUSS ANXIETIES AND CONCERNS WITH OTHERS WHO SHARE THE SAME EXPERIENCES. THIS SHARING STRENGTHENS THE FAMILY BOND AND ENHANCES EVERYONE'S ABILITY TO COPE WITH CANCER. PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM: FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT- VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS; REFERRAL IS ALSO PROVIDED BY LLS'S INFORMATION RESOURCE CENTER. -717 FIRST CONNECTIONS WERE MADE ACROSS THE US IN FY 2016. FORM 990, PAGE 2, PART III, LINE 4C INFORMATION SPECIALISTS ALSO CONDUCT CLINICAL-TRIAL SEARCHES TO HELP PATIENTS WORK WITH THEIR DOCTORS TO FIND OUT ABOUT SPECIFIC CLINICAL TRIALS. THE INFORMATION RESOURCE CENTER ALSO HAS AN EXPANDING IN-DEPTH CLINICAL TRIAL NAVIGATION SERVICE. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. IN FY 2016: - 26,668 INQUIRIES WERE MADE TO OUR INFORMATION SPECIALISTS. - 12,399 UNIQUE INDIVIDUALS RECEIVED INFORMATION AND/OR SUPPORT FROM INFORMATION SPECIALISTS VIA EMAILS, PHONE, AND ANSWER CHATS. -167 PATIENTS WORKED WITH A CLINICAL TRIAL NAVIGATOR TO RECEIVE COMPREHENSIVE ASSISTANCE WITH CLINICAL TRIAL ENROLLMENT; 49% OF THESE PATIENTS ENROLLED ON A CLINICAL TRIAL. THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, DISCUSSION BOARDS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL- TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. INFORMATIONAL MATERIALS ARE AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. MANY DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS ADDITIONALLY, LLS ALSO SPONSORS TELEPHONE- WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. ALSO AVAILABLE THROUGH THE LLS WEBSITE ARE VIRTUAL LECTURES AND VIDEOS FEATURING DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. IN FY 2016: -20,906 INDIVIDUALS PARTICIPATED IN LLS'S ONLINE DISCUSSION BOARDS -LLS PROVIDED 9 LIVE NATIONAL TELEPHONE-WEB EDUCATION PROGRAMS, WITH 3,032 PARTICIPANTS -THERE WERE 24,078 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, 16,612 VIEWS OF VIDEOS. FORM 990, PAGE 2, PART III, LINE 4D D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. FORM 990, PART V, LINE 4B CANADA FORM 990, PAGE 6, PART VI, LINE 6 THE MEMBERS OF LLS CONSIST OF ONE ELECTED REPRESENTATIVE FROM EACH CHAPTER. FORM 990, PAGE 6, PART VI, LINE 7A THE BOARD OF REPRESENTATIVES (REPRESENTING THE CHAPTERS) ELECTS THE MEMBERS OF LLS'S GOVERNING BODY, ITS NATIONAL BOARD OF DIRECTORS. FORM 990, PAGE 6, PART VI, LINE 7B SIGNIFICANT DECISIONS AFFECTING THE CHAPTERS REQUIRE AN APPROVING VOTE BY THE CHAPTER DELEGATES. DECISIONS NOT SIGNIFICANTLY AFFECTING THE CHAPTERS DO NOT REQUIRE APPROVAL FROM THE CHAPTER DELEGATES. FORM 990, PAGE 6, PART VI, LINE 11B THE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CAO & CFO, SR. VICE PRESIDENT OF FINANCE, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE FINAL DRAFT FORM 990 WAS PROVIDED TO THE ENTIRE BOARD OF DIRECTORS PRIOR TO FILING WITH THE IRS. FORM 990, PAGE 6, PART VI, LINE 12C ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES MEMBERS, CHAPTER BOARD MEMBERS, FAMILY SUPPORT GROUP FACILITATORS, AND TNT COACHES ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL FORMS ARE COLLECTED AND THE AUDIT COMMITTEE REVIEWS ANY FORMS DISCLOSING A POSSIBLE CONFLICT OF INTEREST AND DETERMINES WHETHER OR NOT A CONFLICT EXISTS. PART VI, LINE 12 C: ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES ARE RECUSED FROM ANY DISCUSSION WHERE A CONFLICT OF INTEREST EXISTS. ANY QUESTIONS REGARDING COI WILL GO TO THE AUDIT COMMITTEE. FORM 990, PAGE 6, PART VI, LINE 15A THE EXECUTIVE COMMITTEE COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS REVIEWS AND MONITORS THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. IN 2016 THE COMMITTEE OBTAINED A SURVEY OF OTHER NOT- FOR-PROFIT ORGANIZATIONS' COMPENSATION RANGES AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE COMMITTEE MET AND REVIEWED THE COMPENSATION PACKAGE AND WAS DOCUMENTED AND INCLUDED IN THE COMMITTEE MINUTES. FORM 990, PAGE 6, PART VI, LINE 15B THE EXECUTIVE COMMITTEE COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS REVIEWS AND MONITORS THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. IN 2016 THE COMMITTEE OBTAINED A SURVEY OF OTHER NOT- FOR-PROFIT ORGANIZATIONS' COMPENSATION RANGES AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE COMMITTEE MET AND REVIEWED THE COMPENSATION PACKAGE AND IT WAS DOCUMENTED AND INCLUDED IN THE COMMITTEE MINUTES. FORM 990, PAGE 6, PART VI, LINE 17 ILLINOIS, INDIANA, KANSAS, KENTUCKY, LOUISIANA, MASSACHUSETTS, MARYLAND, MAINE, MICHIGAN, MINNESOTA, MISSOURI, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEBRASKA, NEW YORK, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WISCONSIN, WEST VIRGINIA FORM 990, PAGE 6, PART VI, LINE 19 THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990. FORM 990, PART XI, LINE 9 LLS CANADA RESTATEMENT 15,601 FINANCIAL STATEMENT ROUNDING -24 TOTAL 15,577 LLS CANADA RESTATEMENT -15,601 BEAT AML LLC 3 INTERNATIONAL DRIVE RYE BROK NY 10573 RESEARCH NY 2158709 2159709 LLS THE LLS RESEARCH PROGRAMS INC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 133470494 PART VII DE 501C3 11B LLS INC true THE LLS RESEARCH FOUNDATION 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 133709252 PART VII DE 501C3 11B LLS INC true THE LLS OF CANADA 804 2 LANSING SQUARE TORONTO CA M2J4P8 PART VII CA NA false PEARLPOINT CANCER SUPPORT 2817 WEST END AVENUE NASHVILLE TN 37203 581747771 PART VII TN 501C3 7 N/A true false false false false false false false false false false false false false true true false true true false BEAT AML INC R 2158709 COST SCHEDULE R THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY ACTIVITIES AS THE LEUKEMIA & LYMPHOMA SOCIETY, INC., IN CANADA. THE LEUKEMIA SOCIETY RESEARCH PROGRAMS, INC. AND THE LEUKEMIA RESEARCH FOUNDATION, INC. SUPPORT THE ACTIVITIES OF THE LEUKEMIA & LYMPHOMA SOCIETY, INC. THE LEUKEMIA & LYMPHOMA SOCIETY, INC. IS THE 100% CONTROLLING MEMBER OF PEARLPOINT CANCER SUPPORT, INC.